ArticleCancer cell international2017
The inhibition role of miR-22 in hepatocellular carcinoma cell migration and invasion via targeting CD147.
Article in Cancer cell international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- Multi-pathway targeted therapy of MASH-HCC using miR-22.Cell & bioscience · 2025Article
- Targeting STK26 and ATG4B: miR-22-3p as a modulator of autophagy and tumor progression in HCC.Translational oncology · 2025Article
- Advances in the study of the mechanism of action of miR‑22 in liver lesions (Review).Oncology letters · 2024Review
- miR-22 gene therapy treats HCC by promoting anti-tumor immunity and enhancing metabolism.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab.International journal of molecular sciences · 2023Article
- Hsa-miR-22-3p inhibits liver cancer cell EMT and cell migration/ invasion by indirectly regulating SPRY2.PloS one · 2023Article
- Prognostic MicroRNA Fingerprints Predict Recurrence of Early-Stage Hepatocellular Carcinoma Following Hepatectomy.Journal of Cancer · 2023Article
- Article
- Article
- MicroRNA-22-3p and MicroRNA-149-5p Inhibit Human Hepatocellular Carcinoma Cell Growth and Metastasis Properties by Regulating Methylenetetrahydrofolate Reductase.Current issues in molecular biology · 2022Article
- Galectin-1 confers resistance to doxorubicin in hepatocellular carcinoma cells through modulation of P-glycoprotein expression.Cell death & disease · 2022Article
- MiR-22 regulated T cell differentiation and hepatocellular carcinoma growth by directly targeting Jarid2.American journal of cancer research · 2021Article
- The possible role of Sirtuins and microRNAs in hepatocellular carcinoma therapy.Cell cycle (Georgetown, Tex.) · 2020Review
- Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome.Liver research (Beijing, China) · 2020Article
- Overexpression of Galectin-1 and Galectin-3 in hepatocellular carcinoma.Liver research (Beijing, China) · 2020Article
- Genetic Ablation of MiR-22 Fosters Diet-Induced Obesity and NAFLD Development.Journal of personalized medicine · 2020Article
- Serum miR-22 is a novel prognostic marker for acute myeloid leukemia.Journal of clinical laboratory analysis · 2020Article
- Decreased serum exosomal miR-320a expression is an unfavorable prognostic factor in patients with hepatocellular carcinoma.The Journal of international medical research · 2020Article
- miRNAs and lncRNAs inInternational journal of molecular sciences · 2020Review
- Challenges in liver cancer and possible treatment approaches.Biochimica et biophysica acta. Reviews on cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecently, miR-22 is identified as a tumor-suppressing microRNA in many human cancers. CD147 is a novel cancer-associated biomarker that plays an important role in the invasion and metastasis of malignant tumor. However, the involvement of miR-22 in CD147 regulation and hepatocellular carcinoma (HCC) progression and metastasis has not been investigated.
methodsWe measured miR-22 expression level in 34 paired of HCC and matched normal tissues, HCC cell lines by real-time quantitative RT-PCR. Invasion assay, MTT proliferation assay and wound-healing assay were performed to test the invasion and proliferation of HCC cell after overexpression of miR-22. The effect of miR-22 on HCC in vivo was validated by murine xenograft model. The relationship of miR-22 and its target gene CD147 was also investigated.
resultsWe found that the expression of miR-22 in HCC tissues and cell lines were much lower than that in normal control, respectively. The expression of miR-22 was inversely correlated with HCC metastatic ability. Moreover, overexpression of miR-22 could significantly inhibit the HCC cell proliferation, migration and invasion in vitro and decrease HCC tumor growth in vivo. Finally, we found that miR-22 interacted with CD147 and decreased its expression, via a specific target site within the CD147 3'UTR by luciferase reporter assay. The expression of CD147 was inversely correlated with miR-22 expression in HCC tissues.
conclusionOur results suggested that miR-22 was downexpressed in HCC and inhibited HCC cell proliferation, migration and invasion through downregulating cancer-associated gene CD147 which may provide a new bio-target for HCC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.